Gritstone bio is a clinical-stage biotech company developing immunotherapies for cancer and infectious diseases. Its lead product candidate is GRANITE, an immunotherapy for solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy for common solid tumors, and CORAL, a SARS-CoV-2 vaccine platform and therapeutic vaccine candidate for HIV. Gritstone bio has collaborations with bluebird bio and Gilead Sciences and is headquartered in Emeryville, California.